Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LKFT NASDAQ:NGNE NASDAQ:RXRX NASDAQ:TSHA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLKFTLakefront Biotherapeutics American Depositary Shares$30.35-0.1%$28.31$26.42▼$37.78$2.00B0.25162,257 shs101,560 shsNGNENeurogene$32.56-7.9%$29.39$15.93▼$37.27$558.44M1.68243,475 shs230,173 shsRXRXRecursion Pharmaceuticals$3.96+4.2%$3.32$2.77▼$7.18$2.01B119.26 million shs38.01 million shsTSHATaysha Gene Therapies$6.38-2.3%$6.14$2.33▼$7.30$1.88B1.173.84 million shs1.74 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLKFTLakefront Biotherapeutics American Depositary Shares-0.13%+2.29%+8.32%+4.91%+5.25%NGNENeurogene-7.87%+0.87%+22.91%+55.71%+62.43%RXRXRecursion Pharmaceuticals+4.21%+7.32%+19.28%+24.14%-24.71%TSHATaysha Gene Therapies-2.30%-5.20%+16.00%+39.61%+165.83%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLKFTLakefront Biotherapeutics American Depositary Shares$30.35-0.1%$28.31$26.42▼$37.78$2.00B0.25162,257 shs101,560 shsNGNENeurogene$32.56-7.9%$29.39$15.93▼$37.27$558.44M1.68243,475 shs230,173 shsRXRXRecursion Pharmaceuticals$3.96+4.2%$3.32$2.77▼$7.18$2.01B119.26 million shs38.01 million shsTSHATaysha Gene Therapies$6.38-2.3%$6.14$2.33▼$7.30$1.88B1.173.84 million shs1.74 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLKFTLakefront Biotherapeutics American Depositary Shares-0.13%+2.29%+8.32%+4.91%+5.25%NGNENeurogene-7.87%+0.87%+22.91%+55.71%+62.43%RXRXRecursion Pharmaceuticals+4.21%+7.32%+19.28%+24.14%-24.71%TSHATaysha Gene Therapies-2.30%-5.20%+16.00%+39.61%+165.83%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLKFTLakefront Biotherapeutics American Depositary Shares 2.13Hold$36.5020.26% UpsideNGNENeurogene 3.00Buy$84.83160.54% UpsideRXRXRecursion Pharmaceuticals 2.20Hold$8.10104.55% UpsideTSHATaysha Gene Therapies 3.00Buy$12.6297.73% UpsideCurrent Analyst Ratings BreakdownLatest NGNE, TSHA, LKFT, and RXRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/2/2026TSHATaysha Gene Therapies Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$11.006/30/2026TSHATaysha Gene Therapies Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.006/30/2026TSHATaysha Gene Therapies Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$12.00 ➝ $15.006/24/2026TSHATaysha Gene Therapies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/23/2026TSHATaysha Gene Therapies Pivotal ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$14.006/23/2026TSHATaysha Gene Therapies BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$10.00 ➝ $14.006/23/2026TSHATaysha Gene Therapies CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/23/2026TSHATaysha Gene Therapies Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$8.00 ➝ $11.006/22/2026TSHATaysha Gene Therapies Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $10.006/22/2026TSHATaysha Gene Therapies Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.006/9/2026NGNENeurogene HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$70.00(Data available from 7/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLKFTLakefront Biotherapeutics American Depositary Shares$1.26B1.59$0.73 per share41.85$47.57 per share0.64NGNENeurogeneN/AN/AN/AN/A$17.10 per shareN/ARXRXRecursion Pharmaceuticals$74.68M28.10N/AN/A$2.14 per share1.85TSHATaysha Gene Therapies$9.77M187.65N/AN/A$0.90 per share7.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLKFTLakefront Biotherapeutics American Depositary Shares$363.05M-$1.41N/AN/AN/AN/AN/AN/A8/10/2026 (Estimated)NGNENeurogene-$90.35M-$4.55N/AN/AN/AN/A-37.88%-34.70%8/10/2026 (Estimated)RXRXRecursion Pharmaceuticals-$644.76M-$1.20N/AN/AN/A-842.95%-54.33%-40.60%8/4/2026 (Estimated)TSHATaysha Gene Therapies-$109M-$0.38N/AN/AN/AN/A-56.07%-40.16%8/11/2026 (Estimated)Latest NGNE, TSHA, LKFT, and RXRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2026Q2 2026RXRXRecursion Pharmaceuticals-$0.25N/AN/AN/A$11.20 millionN/A5/12/2026Q1 2026NGNENeurogene-$1.2963-$1.39-$0.0938-$1.39N/AN/A5/6/2026Q1 2026LKFTLakefront Biotherapeutics American Depositary Shares-$1.27$0.25+$1.52$0.25$11.26 million$8.75 million5/6/2026Q1 2026RXRXRecursion Pharmaceuticals-$0.30-$0.22+$0.08-$0.22$15.78 million$6.47 million5/6/2026Q1 2026TSHATaysha Gene Therapies-$0.10-$0.12-$0.02-$0.12$0.76 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthLKFTLakefront Biotherapeutics American Depositary SharesN/AN/AN/AN/AN/ANGNENeurogeneN/AN/AN/AN/AN/ARXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ATSHATaysha Gene TherapiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLKFTLakefront Biotherapeutics American Depositary SharesN/A30.4830.30NGNENeurogeneN/A13.0813.08RXRXRecursion Pharmaceuticals0.015.475.47TSHATaysha Gene Therapies0.2314.0414.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLKFTLakefront Biotherapeutics American Depositary Shares32.46%NGNENeurogene52.37%RXRXRecursion Pharmaceuticals89.06%TSHATaysha Gene Therapies77.70%Insider OwnershipCompanyInsider OwnershipLKFTLakefront Biotherapeutics American Depositary Shares2.91%NGNENeurogene11.68%RXRXRecursion Pharmaceuticals6.65%TSHATaysha Gene Therapies3.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLKFTLakefront Biotherapeutics American Depositary Shares1,31065.90 million63.98 millionOptionableNGNENeurogene9015.80 million13.96 millionOptionableRXRXRecursion Pharmaceuticals400529.91 million494.67 millionOptionableTSHATaysha Gene Therapies180287.36 million276.50 millionOptionableNGNE, TSHA, LKFT, and RXRX HeadlinesRecent News About These CompaniesTaysha: 'Buy' On Interim Analysis Of TSHA-102 First Half 2027 And Broad Label PotentialJune 30, 2026 | seekingalpha.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of "Buy" from AnalystsJune 29, 2026 | americanbankingnews.comTaysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsJune 25, 2026 | finanznachrichten.deTaysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical ...June 25, 2026 | enidnews.comETaysha Gene Therapies Announces Major Equity Financing DealJune 25, 2026 | tipranks.comTaysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific MeetingJune 25, 2026 | globenewswire.comTaysha Gene Therapies shares tumble following pricing shares at $6.00 to raise $200MJune 25, 2026 | msn.comTaysha Gene Therapies Prices $200 Million Public Offering of Common Stock and Pre-Funded WarrantsJune 24, 2026 | quiverquant.comQTaysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsJune 24, 2026 | globenewswire.comTaysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsJune 24, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Taysha Gene Therapies (TSHA) and AbbVie (ABBV)June 23, 2026 | theglobeandmail.comTaysha Gene Therapies, Inc. (TSHA) Discusses Longer-Term Clinical Data and Program Update for TSHA-102 in Rett Syndrome - SlideshowJune 23, 2026 | seekingalpha.comTaysha Gene Therapies, Inc. (TSHA) Discusses Longer-Term Clinical Data and Program Update for TSHA-102 in Rett Syndrome TranscriptJune 22, 2026 | seekingalpha.comTaysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 ...June 22, 2026 | markets.businessinsider.comTaysha Advances Rett Syndrome Programme as Pivotal Trial Enrollment Completes (TSHA)June 22, 2026 | msn.comTaysha Gene Therapies (TSHA) Stock Looks Undervalued After Sharp Three Year RecoveryJune 13, 2026 | finance.yahoo.comIs Taysha Gene Therapies, Inc. (TSHA) A Good Stock To Buy Now?June 11, 2026 | finance.yahoo.comTaysha Gene Therapies Grants Restricted Stock Units and Stock Options to New EmployeesJune 5, 2026 | quiverquant.comQTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 5, 2026 | globenewswire.comTaysha Gene Therapies Shareholders Back Governance and LeadershipJune 2, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNGNE, TSHA, LKFT, and RXRX Company DescriptionsLakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT$30.35 -0.04 (-0.13%) As of 07/6/2026 04:00 PM EasternGalapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.Neurogene NASDAQ:NGNE$32.56 -2.78 (-7.87%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$33.45 +0.89 (+2.73%) As of 08:34 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.Recursion Pharmaceuticals NASDAQ:RXRX$3.96 +0.16 (+4.21%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$3.96 0.00 (-0.13%) As of 09:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Taysha Gene Therapies NASDAQ:TSHA$6.38 -0.15 (-2.30%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$6.54 +0.16 (+2.43%) As of 08:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Flash Crash or Cash? The AI Hardware Reset Investors Can’t Ignore 2 Short Squeezes for Summer Speculation: What the Bears Are Getting Wrong How TeraWulf’s Anthropic Deal Booted Up a $19B AI Empire Small-Cap ETFs Poised for Big Growth as Rate Outlook Shifts KBR Insiders Are Buying While the Market Misreads Its Spinoff Doug Casey Calls AI a Super Bubble, Bets on Energy, Gold Miners and Grains Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
